Seeing Is Believing
Currently out of the existing stock ratings of Jami Rubin, 39 are a BUY (60.94%), 17 are a HOLD (26.56%), 8 are a SELL (12.5%).
Analyst Jami Rubin, currently employed carries an average stock price target met ratio of 84.62% that have a potential upside of 29.86% achieved within 484 days. Previously, Jami Rubin worked at GOLDMAN SACHS.
Jami Rubin’s has documented 143 price targets and ratings displayed on 13 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 01-Oct-2018.
Analyst best performing recommendations are on ALNY (ALNYLAM PHARMACEUTICALS).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 11/6/2017. The price target of $13 was fulfilled within 11 days with a profit of $0.67 (5.43%) receiving and performance score of 4.94.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$39.27 (23.70%)
5 days ago
(15-Nov-2024)
2/3 (66.67%)
$39.27 (23.70%)
507
Buy
$200
$34.27 (20.68%)
$190
7 days ago
(13-Nov-2024)
12/13 (92.31%)
$28.57 (16.67%)
490
Buy
$215
$49.27 (29.73%)
$226
8 days ago
(12-Nov-2024)
8/10 (80%)
$39.86 (22.76%)
293
Buy
$224
$58.27 (35.16%)
$231
8 days ago
(12-Nov-2024)
12/15 (80%)
$48.86 (27.90%)
488
Buy
$221
$55.27 (33.35%)
$171
14 days ago
(06-Nov-2024)
22/23 (95.65%)
$18.37 (9.07%)
427
What Year was the first public recommendation made by Jami Rubin?